US biopharmaceutical company Blend Therapeutics has appointed pharmaceutical industry veteran Richard Wooster as chief scientific officer. 7 January 2014
French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice President in charge of Human Resources of the Ipsen group in place of Etienne de Blois. 19 December 2013
Sydney-based companion diagnostic and personalized medicine company Clarity has appointed Alan Taylor as its new executive chairman to the board. 19 December 2013
New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments to its executive leadership team. The appointments are part of Forest’s plans to broaden the organization as part of Project Rejuvenate. 16 December 2013
Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department following the resignation of former HR vice president Teddy Hebo Larsen. 16 December 2013
Swiss drug major Roche (ROG: SIX) has issued a list of members of the Board of Directors to be elected at its AGM on March 4, 2014. The board proposes Christoph Franz to be elected as Chairman of the Board. 10 December 2013
Denmark-based small molecule lead discovery company Nuevolution A/S has appointed Ton Berkien as Chief Business Officer from January 1. 9 December 2013
Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen has decided to retire as chairman and board member. 9 December 2013
The UK’s ‘Golden Triangle’ of biotech innovation can compete on the world stage, AstraZeneca (LSE: AZN) chief executive Pascal Soriot told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
Japan’s largest drugmaker, Takeda Pharmaceutical, says that Christophe Weber has been approved at the company's board of directors meeting to become chief operating officer and candidate as the next chief executive of the company. 29 November 2013
US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has named Yong-Jun Liu as the company’s new head of research. 20 November 2013
UK-based biotech company Immunocore has appointed Jonathan Knowles as the new executive chairman of the board of directors with immediate effect. 20 November 2013
To support its ongoing success as a BioPharma leader, US drug major Bristol-Myers Squibb says it is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization, and has announced a series of related changes within its senior management team. 14 November 2013
AstraZeneca today announced that Marc Dunoyer has been appointed chief financial officer and will join the company board as an executive director, effective tomorrow. 31 October 2013
Merck KGaA announced today that Gerhard Schmitz will join the pharmaceutical, chemical and life science company as the new Head of Global Accounting from November 1. 30 October 2013
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024